Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
VANCOUVER, BC, March 8, 2024 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX:NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, congratulates Mind Medicine (“MindMed”NASDAQ: MNMD, Cboe Canada: MMED) on the positive data generated from its Phase 2b clinical trial of MM120 (lysergide d-tartrate) for the treatment of generalized anxiety disorder (“GAD”). The study showed that four weeks after a single 100-microgram dose of MM120, 48 percent of the participants achieved remission and no longer showed clinically significant anxiety, and 65 percent showed clinically meaningful improvement. Based on initial clinical data from the Phase 2b trial and the significant unmet medical need in treating GAD, the U.S. Food & Drug Administration (“FDA”) has designated MM120 for GAD as a breakthrough therapy. 1